BridgeBio Pharma, Inc.

BBIO

US10806X1028

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:44:51 2024-07-17 pm EDT			5-day change	1st Jan Change
27.97 ^USD	-4.38%		+5.57%	-30.57%

Jun. 18	BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial	MT
Jun. 18	BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)	CI

BridgeBio Pharma Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

January 30, 2018 at 08:00 am EST

BridgeBio Pharma announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.

Latest news about BridgeBio Pharma, Inc.

BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial	Jun. 18	MT
BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)	Jun. 18	CI
Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM	Jun. 12
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Jun. 04	MT
BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment	Jun. 04	MT
Transcript : BridgeBio Pharma, Inc. - Special Call	Jun. 04
BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia	Jun. 04	CI
Transcript : BridgeBio Pharma, Inc. - Special Call	May. 29
UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating	May. 28	MT
Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	May. 15
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population	May. 13	CI
Certain Restricted Stock Unit Awards of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	May. 05	CI
Certain Options of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	May. 05	CI
Certain Common Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	May. 05	CI
BridgeBio Pharma Shares Decline After Q1 Financial Results	May. 02	MT
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M	May. 02	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
BridgeBio Pharma, Inc. announced that it has received $200 million in funding from a group of investors	May. 01	CI
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	Apr. 07	CI
JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	Mar. 20	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	Mar. 19	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	Mar. 11	MT
BridgeBio Pharma Prices $250 Million Stock Offering	Mar. 06	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Mar. 05	MT
BridgeBio Pharma Commences $250 Million Share Offering	Mar. 04	MT

Chart BridgeBio Pharma, Inc.

Duration

Period

More charts

Company Profile

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BridgeBio Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.25 USD

Average target price

49.46 USD

Spread / Average Target

+69.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BRIDGEBIO PHARMA, INC.	-30.57%	5.47B
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	42.34B
BIOGEN INC.	-11.32%	32.76B
UCB	+79.34%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-12.27%	16.31B
INCYTE CORPORATION	+3.74%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.23B
ALTEOGEN INC.	+178.17%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.80%	8.97B

Biopharmaceuticals

BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Pharmaceuticals

BridgeBio Pharma Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

EPS Revisions